<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perioperative uses and doses of intravenous opioid agents*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perioperative uses and doses of intravenous opioid agents*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Perioperative uses and doses of intravenous opioid agents*</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1"><span style="color: #ff0000;"></span>Drug</td> <td class="subtitle1">Induction of general anesthesia</td> <td class="subtitle1">Maintenance of general anesthesia</td> <td class="subtitle1">Monitored anesthesia care (MAC)</td> <td class="subtitle1">Comments</td> <td class="subtitle1">Management of acute postoperative pain</td> </tr> <tr class="divider_bottom"> <td>Fentanyl</td> <td> <p>Bolus dose(s): 25 to 100 mcg or 0.5 to 1 mcg/kg; may be administered in divided doses.</p> High-dose opioid induction (ie, "cardiac induction"): 10 to 25 mcg/kg.</td> <td> <p>Bolus dose(s): 25 to 50 mcg as needed.</p> Maintenance infusion to supplement TIVA: 1 to 2 mcg/kg per hour.<sup>¶</sup></td> <td>Bolus doses: 25 to 50 mcg.</td> <td> <p>High-dose fentanyl is not commonly used for anesthetic induction, but may be selected for patients with severe myocardial dysfunction.</p> Continuous infusions are not commonly used if extubation is planned at the end of the procedure because emergence may be delayed due to a long context-sensitive half time.</td> <td>Bolus doses: 25 to 50 mcg every five minutes until patient is comfortable.</td> </tr> <tr class="divider_bottom"> <td>Remifentanil</td> <td>Remifentanil intubation technique without an NMBA: 3 to 5 mcg/kg administered with an induction dose of propofol and ephedrine 10 mg.</td> <td>Maintenance infusion to supplement inhalation anesthesia or TIVA: 0.05 to 0.3 mcg/kg per minute.<br/> (Some clinicians administer a loading dose, typically 0.5 to 1 mcg/kg over 60 to 90 seconds.)</td> <td>Before placement of regional block: <ul class="decimal_heading"> <li>90 seconds before: 1 mcg/kg. </li> <li>5 minutes before: 0.5 mcg/kg per minute. </li> </ul> <br/> Maintenance dose: Infusion at 0.05 to 0.3 mcg/kg per minute.</td> <td>A different opioid or another analgesic agent or technique should be initiated before the remifentanil infusion is discontinued to ensure adequate postoperative analgesia.</td> <td> </td> </tr> <tr class="divider_bottom"> <td>Sufentanil</td> <td> <p>Bolus dose(s): 0.05 to 0.1 mcg/kg in divided doses.</p> High-dose opioid induction (ie, "cardiac induction"): 1 to 3 mcg/kg.</td> <td> <p>Bolus dose(s): 5 to <span style="color: black;">10</span> mcg as needed.</p> Maintenance infusion to supplement TIVA: 0.05 to 0.15 mcg/kg per hour (or 0.0008 to 0.0025 mcg/kg per minute).</td> <td> </td> <td>Infusion is typically discontinued 30 to 45 minutes prior to end of surgery for a predictable decline in concentration.</td> <td> </td> </tr> <tr class="divider_bottom"> <td>Alfentanil</td> <td> <p>Bolus dose(s): 500 mcg (which may be repeated), or 50 to 100 mcg/kg administered in divided doses.</p> Maintenance: 0.5 to 1.5 mcg/kg per minute.</td> <td> <p>Bolus dose(s): 500 mcg as needed.</p> Maintenance infusion to supplement TIVA: 0.5 to 1.5 mcg/kg per minute.</td> <td> </td> <td>Infusion is typically discontinued 30 to 45 minutes prior to end of surgery for a predictable decline in concentration.</td> <td> </td> </tr> <tr class="divider_bottom"> <td>Hydromorphone</td> <td> </td> <td>Bolus doses: 0.2 to 0.5 mg as needed.</td> <td> </td> <td>It is ideal to use hydromorphone towards the end of surgery (rather than during surgery) in order to provide pain relief in the PACU and beyond.</td> <td> <p>Initial bolus doses of 0.2 to 0.5 mg every five minutes until pain is relieved or unwanted side effects become evident.</p> After initial pain control, typical doses are 0.2 to 0.5 mg every three to four hours.</td> </tr> <tr class="divider_bottom"> <td>Morphine</td> <td> </td> <td>Bolus doses: 1 to 2 mg as needed.</td> <td> </td> <td>It is ideal to use morphine towards the end of surgery (rather than during surgery) in order to provide pain relief in the PACU and beyond. Typically, 1 to 2 mg increments to a total of approximately 0.05 to 0.2 mg/kg IBW are administered about 20 minutes prior to the expected time of extubation.</td> <td> <p>Initial bolus doses of 1 to 3 mg every five minutes until pain is relieved or unwanted side effects become evident.</p> After initial pain control, typical doses are 2 to 4 mg IV every three hours.</td> </tr> <tr> <td>Methadone</td> <td>0.1 to 0.2 mg/kg (ideal body weight) IV up to 20 mg, given post-induction.</td> <td> </td> <td> </td> <td> <p>A single post-induction dose has been shown to have overall opioid-sparing effects throughout the perioperative period in various surgical populations. Evidence is equivocal regarding whether a single post-induction dose results in clinically significant respiratory depression.</p> Data is lacking on the effect of a single dose of methadone on QTc. Consider other options for patients with underlying prolonged QTc.</td> <td>Repeat dosing is not recommended as redistribution half-life is relatively short (approximately 1 minute), but once exceeded the elimination half-life is much longer (approximately 30 hours).</td> </tr> </tbody></table></div><div class="graphic_footnotes">TIVA: total intravenous anesthesia; NMBA: neuromuscular blocking agents; PACU: post-anesthesia care unit; IBW: ideal body weight; IV: intravenous.<br/>* Opioids are used as adjuvant agents during induction and maintenance of general anesthesia and during monitored anesthesia care (MAC).<br/>¶ Fentanyl infusion is not commonly used if extubation is planned at the end of the procedure.</div><div id="graphicVersion">Graphic 111779 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
